By a News Reporter-Staff News Editor at Women's Health Weekly -- Investigators publish new report on Oncology. According to news reporting originating in Pamplona, Spain, by NewsRx journalists, research stated, "Breast cancer is a heterogeneous group of neoplasms predominantly originating in the terminal duct lobular units. It represents the leading cause of cancer death in women and the survival frequencies for patients at advanced stages of the disease remain low."
The news reporters obtained a quote from the research from the University of Navarra, "New treatment options need to be researched to improve these rates. The anti-tumor ether lipid edelfosine (ET) is the prototype of a novel generation of promising anticancer drugs. However, it presents several drawbacks for its use in cancer therapy, including gastrointestinal and hemolytic toxicity and low oral bioavailability. To overcome these obstacles, ET was encapsulated in Precirol ATO 5 lipid nanoparticles (ET-LN), and its anti-tumor potential was in vitro tested in breast cancer. The formulated ET-LN were more effective in inhibiting cell proliferation and notably decreased cell viability, showing that the cytotoxic effect of ET was considerably enhanced when ET was encapsulated. In addition, ET and ET-LN were able to promote cell cycle arrest at G1 phase. Moreover, although both treatments provoked an apoptotic effect in a time-dependent manner, such anti-tumor effects were noticeably improved with ET-LN treatment."
According to the news reporters, the research concluded: "Therefore, our results indicate that encapsulating ET in LN played an essential role in improving the efficacy of the drug."
For more information on this research see: Efficacy of edelfosine lipid nanoparticles in breast cancer cells. International Journal of Pharmaceutics, 2013;454(2):720-726. International Journal of Pharmaceutics can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; International Journal of Pharmaceutics - www.elsevier.com/wps/product/cws_home/505513)
Our news correspondents report that additional information may be obtained by contacting M.A. Aznar, University of Navarra, Sch Pharm, Dept. of Pharm & Pharmaceut Technol, E-31080 Pamplona, Spain. Additional authors for this research include B. Lasa-Saracibar, A.E.H. de Mendoza and M.J. Blanco-Prieto (see also Oncology).
Keywords for this news article include: Spain, Europe, Pamplona, Oncology, Treatment, Nanoparticle, Breast Cancer, Nanotechnology, Women's Health, Emerging Technologies
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC